Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 62,291 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 62,291 shares of Immunome stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $26.23, for a total value of $1,633,892.93. Following the completion of the sale, the director directly owned 92,211 shares of the company’s stock, valued at approximately $2,418,694.53. This trade represents a 40.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00.
• On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The stock was sold at an average price of $26.07, for a total transaction of $263,958.75.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Price Performance

Shares of Immunome stock traded up $1.74 during trading hours on Wednesday, reaching $27.99. The company had a trading volume of 1,561,300 shares, compared to its average volume of 1,383,354. The firm has a market cap of $3.17 billion, a PE ratio of -11.76 and a beta of 2.07. Immunome, Inc. has a one year low of $8.66 and a one year high of $28.04. The business has a fifty day simple moving average of $21.73 and a 200 day simple moving average of $22.18.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, research analysts forecast that Immunome, Inc. will post -2.06 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IMNM. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Truist Financial lifted their price objective on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup restated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Wedbush upped their target price on Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and an average target price of $34.64.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP bought a new position in Immunome in the second quarter valued at $25,000. E Fund Management Co. Ltd. purchased a new position in shares of Immunome in the 2nd quarter worth about $248,000. Citizens Financial Group Inc. RI purchased a new position in shares of Immunome in the 2nd quarter worth about $424,000. BlackRock Inc. bought a new position in shares of Immunome during the 2nd quarter valued at about $186,588,000. Finally, Deutsche Bank AG purchased a new position in shares of Immunome during the 2nd quarter valued at about $2,365,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.